MedImmune, LLC
One MedImmune Way
Gaithersburg
Maryland
20878
United States
Tel: 301-398-0000
Fax: 301-398-9000
Website: http://www.medimmune.com/
About MedImmune, LLC
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.
With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.
352 articles about MedImmune, LLC
-
MedImmune, Inc. Breaks Ground On New Biologics Manufacturing Facility In Frederick, Maryland, A $250-Million Expansion
9/13/2006
-
The Day In Review: FDA Pays $500 Million For Cancer Drug
8/28/2006
-
MedImmune, Inc. Files Investigational New Drug Application For MT103
8/21/2006
-
The Day In Review: Neurochem, Inc. Climbs On Approvable Letter
8/14/2006
-
MedImmune, Inc. Replies To FDA's Complete Response Letter For New Formulation Of FluMist(R)
8/14/2006
-
MedImmune, Inc. Promotes Ed Mathers To Executive Vice President, Corporate Development And Venture
8/14/2006
-
MedImmune, Inc. Submits Refrigerator-Stable Formulation Of FluMist(R) To FDA For Approval In Younger Children
7/31/2006
-
MedImmune, Inc. Begins Shipping FluMist(R) For 2006-2007 Flu Season
7/25/2006
-
MedImmune, Inc. And Micromet Report On Novel Anti-cancer BiTE(R)
7/21/2006
-
MedImmune, Inc. Reports 2006 Second-Quarter And Six-Month Financial Results
7/20/2006
-
MedImmune, Inc. Receives FDA Approval To Use Reverse Genetics Technology For FluMist(R) Vaccine Production
7/6/2006
-
MedImmune, Inc. Closes Sale Of $1.15 Billion Convertible Senior Notes
6/29/2006
-
MedImmune, Inc. Broadens Efforts To Develop Vaccines To Help Prevent RSV And Other Important Pediatric Respiratory Diseases
6/29/2006
-
MedImmune, Inc. Prices $1B Convertible Senior Notes
6/23/2006
-
MedImmune, Inc. To Offer $1 Billion Convertible Senior Notes
6/22/2006
-
MedImmune, Inc. To Announce 2006 Second Quarter Financial Results On July 20, 2006
6/19/2006
-
MedImmune, Inc. And National Institutes of Health (NIH) Begin Clinical Testing Of A Live, Attenuated Intranasal Vaccine Against An H5N1 Avian Influenza Virus
6/15/2006
-
MedImmune, Inc.'s Update To Investors At Goldman, Sachs & Co. Healthcare Conference Highlights Progress Of Key Programs And Initiatives
6/14/2006
-
MedImmune, Inc. To Present At Goldman, Sachs & Co. Twenty-Seventh Annual Global Healthcare Conference
6/7/2006
-
BioSpace Inc. Unveils 2006 BioCapital™ Hotbed Campaign
5/25/2006